Astellas Pharma (OTCMKTS:ALPMY) Reaches New 52-Week Low at $9.15

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as $9.15 and last traded at $9.34, with a volume of 692432 shares changing hands. The stock had previously closed at $9.27.

Astellas Pharma Stock Performance

The company’s 50-day moving average price is $10.73 and its two-hundred day moving average price is $11.64. The company has a market cap of $17.14 billion, a P/E ratio of 23.95, a price-to-earnings-growth ratio of 1.28 and a beta of 0.32. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Monday, February 5th. The company reported $0.12 earnings per share (EPS) for the quarter. The firm had revenue of $2.86 billion for the quarter. Astellas Pharma had a net margin of 0.08% and a return on equity of 6.39%. As a group, equities analysts forecast that Astellas Pharma Inc. will post 0.35 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.